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Abstract
Background: Significant associations between visceral fat and alterations in plasma fatty acids have been identified
in overweight individuals. However, there are scant data regarding the relationships of the visceral fat area (VFA)
with the plasma fatty acid profiles and desaturase activities following weight loss. We investigated the effect of
weight loss with mild calorie restriction on the circulating fatty acid profiles and desaturase activities in nondiabetic
overweight subjects with high VFA.
Methods: Eighty overweight subjects with high VFA (L4 VFA ≥100 cm2) were randomized into the 12-week
mild-calorie-restriction (300 kcal/day) or control groups.
Results: Comparison of the percent of body weight changes between groups revealed that the weight-loss
group had greater reductions in body weight. The VFA decreased by 17.7 cm2 from baseline in the weight-loss
group (P < 0.001). At follow-up, the weight-loss group showed greater reductions in serum triglycerides, insulin, and
HOMA-IR than the control group. Significantly greater reductions in total saturated fatty acids, palmitic acid,
stearic acid, total monounsaturated fatty acids, palmitoleic acid, oleic acid, eicosadienoic acid, and dihomo-γ-
linolenic acid levels were detected in the weight-loss group compared with the control group after adjusting
for baseline values. Following weight loss, C16 Δ9-desaturase activity was significantly decreased and Δ5-
desaturase activity was significantly increased, and the changes were greater in the weight-loss group than in
the control group.
Conclusions: The results suggest that mild weight loss improves abdominal obesity, overall fatty acid profiles,
and desaturase activities; therefore, mild calorie restriction has potential health benefits related to obesity-related diseases
in overweight subjects with high VFA.
Trial registration: NCT02992639. Retrospectively registered 11 December 2016.
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Background
A visceral fat area (VFA) cutoff of 100 cm2 was established
to predict the risk of obesity-related health risks, including
insulin resistance (IR), metabolic syndrome, and diabetes,
in Asian populations [1]. Compared with abdominal sub-
cutaneous fat, visceral fat is more metabolically active in
the fasting state [2, 3]. Compared with other weight-loss
methods, calorie restriction tends to reduce more visceral
than subcutaneous adipose tissue [4]. It is known that
plasma fatty acid composition mirrors not only dietary
fatty acid composition but also endogenous fatty acid syn-
thesis, in which desaturases play important roles [5]. In
endogenous fatty acid synthesis, C16 Δ9-desaturase
(C16:1/C16:0) activity is known to be high in conditions
of diabetes and abdominal obesity. Additionally, an inverse
relation between Δ5-desaturase activity (C20:4, n-6/C20:3,
n-6) and diabetes risk and a direct relation between Δ6-
desaturase activity (C18:3, n-6/C18:2, n-6) and IR have
been reported. Pan et al. [6] reported that obesity is
related to increased Δ9-desaturase activity and reduced
Δ5-desaturase activity. Several previous studies observed
that low Δ5-desaturase activity is linked to increased risk
of type 2 diabetes and insulin resistance among Japanese
adults [7, 8]. Zhao et al. [9] also noted that Δ5-desaturase
activity is inversely associated with metabolic abnormal-
ities among obese Chinese subjects. In a Swedish study,
Δ5-desaturase activity was found to be inversely associated
with obesity and insulin resistance, whereas Δ6-desaturase
activity demonstrated positive associations [10].
Significant associations between visceral fat amount
and alterations in serum fatty acids have been identified
in overweight individuals [11]. However, there are scant
data regarding the relations between changes in VFA
and changes in circulating fatty acid profiles and desa-
turase activities following weight loss. Research is re-
quired to determine the amount of visceral fat reduction
with calorie restriction that is necessary to induce favor-
able metabolic changes in the overall fatty acid profile.
Therefore, in this study, we investigated the effects of
weight loss with mild calorie restriction (a 300 kcal/day
intake reduction) on circulating fatty acid profiles and
desaturase activities in nondiabetic overweight subjects
with high VFA [VFA at the 4th lumbar vertebrae (L4
VFA) ≥ 100 cm2].
Methods
Study subjects
Study subjects were recruited through advertisements
posted in Seoul. Based on the data screened by the Clin-
ical Nutrition Lab, Yonsei University, overweight subjects
[25.0 kg/m2 ≤ body mass index (BMI) < 30 kg/m2] were
referred to the Department of Internal Medicine, Yonsei
University Severance Hospital. After their health and basic
blood tests, including serum glucose, were rechecked,
individuals who met the study criteria were recommended
for study participation. The inclusion criteria were as fol-
lows: age between 20 and 60 years; absence of pregnancy
or breastfeeding; stable body weight (body weight change
< 1 kg in the 3 months before screening); BMI between 25
and 30 kg/m2; high L4 VFA (L4 VFA ≥ 100 cm2); absence
of hypertension, type 2 diabetes, cardiovascular disease,
and thyroid disease; and no use of medication affecting
body weight, energy expenditure, or glucose control for
6 months prior to screening. Subjects were excluded if
they had a history of Cushing syndrome, malignancy, or
liver disease, including chronic viral hepatitis, autoimmune
hepatitis, primary biliary cirrhosis, and drug-induced liver
disease. Male and female subjects whose alcohol consump-
tion was > 40 and > 20 g/day, respectively, and subjects
with a history of intentional weight reduction in the
6 months before the current study were excluded. Finally,
those who consented to participate in the program were
included in this study. The purpose of the study was care-
fully explained to all participants, and written consent was
obtained prior to their participation. The protocol was
approved by the Institutional Review Board of Yonsei Uni-
versity and Yonsei University Severance Hospital in
accordance with the Helsinki Declaration.
Study design and intervention
The basic framework of the present study was based on
a previous study [12]. A 12-week, placebo-controlled,
randomized study was conducted with 80 high VFA,
nondiabetic overweight subjects (L4 VFA ≥ 100 cm2).
Subjects were divided into two groups: a weight-loss
group with 12 weeks of mild calorie restriction (a
300 kcal/day intake reduction) or a control group with
no treatment (NCT02992639; http://www.clinicaltrials.-
gov/). Randomization was achieved by computer-
generated block randomization (placebo:test = 1:1).
Protocol for weight loss
The subjects in the weight-loss group followed a 12-week
weight-loss program comprising a 300 kcal/day reduction
of their usual caloric intake. Basically, the subjects were
instructed to remove 1/3 of a bowl of rice (approximately
100 kcal; a bowl of rice is approximately 300 kcal per meal,
according to the food composition table from the Rural
Development Administration of Korea [13]) from one
meal a day for easier application of the 300 kcal/day
deficit. Moreover, based on each subject’s reported food
intake, an individualized and nutritionally balanced diet
plan was produced by a trained nutritionist to achieve the
goal of losing a minimum of 3% of initial body weight. The
instructions included food choices, cooking methods,
reductions in snack consumption frequency, low-calorie
substitutions for high-calorie foods, low-fat foods, and lim-
itations on simple sugar consumption. The subjects in the
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control group were instructed to maintain their usual diet-
ary and physical activity habits during the study period.
Daily energy intake and physical activity measurements
At baseline, the subjects’ usual dietary intakes were
assessed via 24-h recall and semiquantitative food fre-
quency questionnaires completed with the nutritionist’s
assistance. In addition, a standardized 3-day dietary record
was obtained from each participant at week 6 and 12.
These records were completed at home following detailed
instructions from the nutritionist. A computerized version
of the Korean Nutrition File (Can-Pro 3.0; The Korean
Nutrition Society, Seoul, Korea) was used to determine
the macronutrient contents of foods and total daily energy
intakes. On the same days as the dietary records, 3-day
physical activity records were completed at home. The
total energy expenditure (TEE) (kcal/day) was calculated
from activity patterns, including the basal metabolic rate
(BMR), physical activity for 24 h, and the specific dynamic
action of food. Each subject’s BMR was calculated using
the Harris-Benedict equation.
Anthropometric parameters and body composition
measurements
Detailed information was previously published [14].
Briefly, all data were acquired at baseline and week 12.
Body weight (Inbody370; Biospace, Cheonan, Korea),
height, waist circumference, and blood pressure (BP)
were measured. BMI was calculated in units of kilogram
per square meter (kg/m2). The abdominal fat distribu-
tion was measured at L4 by computed tomography
(CT). The scanning parameters were a slice thickness of
1 mm at 200 mA and 120 kVp, with a 48-cm field of
view. Abdominal adipose tissue was determined using
the attenuation range from − 150 to − 50 Hounsfield
units in the CT images. The body composition of the
study participants was measured via dual-energy X-ray
absorptiometry (DEXA) to determine the fat percentage,
fat mass, and lean body mass.
Blood collection and biochemical assessments
Details were provided previously [14]. Blood samples
were collected after an overnight fast of at least 12 h.
Venous blood specimens were collected in EDTA-
treated tubes and serum tubes. The blood samples were
centrifuged to obtain plasma and serum samples, which
were then stored at − 70 °C. The levels of serum-fasting
glucose, insulin, triglycerides (TGs), total cholesterol,
and high-density lipoprotein (HDL) cholesterol were
measured [15]. The IR and low-density lipoprotein
(LDL) cholesterol levels were calculated using the equa-
tions of homeostatic model assessment (HOMA) and
the Friedewald formula, respectively: HOMA-IR = [fast-
ing insulin (μIU/mL) × fasting glucose (mg/dL)]/405;
Friedewald formula: LDL cholesterol = total cholesterol
– [HDL cholesterol + (TG/5)].
Metabolite extraction and gas chromatography–mass
spectrometry (GC-MS) analysis
The details of the GC-MS procedure have been previ-
ously published [16]. Briefly, plasma samples (100 μL)
were placed into PTEE screw-capped Pyrex tubes. An
internal standard compound containing heptadecanoic
acid (500 μL, 25 ppm in n-hexane) and methanol (2 mL)
were added to the samples. After vortexing, acetyl chlor-
ide (100 μL) was added slowly, and the tubes were then
heated at 95 °C for 1 h. After cooling on ice, 6% potas-
sium carbonate (5 mL) was added to the tubes. The
tubes were centrifuged (4 °C, 3000 rpm, 5 min), and the
clear n-hexane top layer (100 μL), including the fatty
acid methyl esters (FAME), was then transferred into a
vial prior to GC-MS analysis.
GC-MS analyses were performed on an Agilent Tech-
nologies 7890 N gas chromatograph coupled with an
Agilent Technologies 5977A quadrupole mass selective
spectrometer with a triple-axis detector (Agilent, Palo
Alto, CA, USA) in the electron ionization (70 eV) and
full scan monitoring (m/z 50–800) modes. The injection
volume of the samples was 1 μL in the splitless mode.
The fatty acid methyl esters of all samples were sepa-
rated on a VF-WAX column (Agilent Technologies,
Middelburg, Netherlands) with helium as a carrier gas.
The temperature program was as follows: (1) initial
temperature of 50 °C for 2.3 min, (2) increase to 175 °C
at 50 °C/min, and (3) increase to 230 °C at 2 °C/min.
The metabolites in the samples were identified by com-
paring their relative retention times and mass spectra
with those of authentic reference standards. The relative
levels of metabolites were calculated by comparing their
peak areas to those of the internal standard compound.
Statistical analysis
The statistical analyses were conducted with SPSS ver-
sion 23.0 software (IBM/SPSS, Chicago, IL, USA).
Skewed variables were logarithmically transformed. An
independent t-test compared continuous variables be-
tween the control and weight-loss groups. A paired t-test
was used to compare continuous variables at baseline
and follow-up within each group. For the comparison of
categorical variables, a chi-squared test was conducted.
A general linear model test was performed to adjust the
baseline values of the changed values. A Pearson’s cor-
relation coefficient was used to examine the relations
among variables. A heat map was created using Multiple
Experiment Viewer (MeV) version 4.9.0 (http://
www.tm4.org/) to visualize and evaluate the relations
among variables in the study population. The results are
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expressed as the mean ± standard error (SE). A two-
tailed P < 0.05 was considered statistically significant.
Results
The dropout rate was less than 10% in the control (n = 2)
and weight-loss (n = 3) groups. Participants were excluded
for personal reasons (n = 4) and lack of a blood sample for
GC-MS analysis (n = 1).
Effects of mild calorie restriction on clinical and
biochemical characteristics at baseline and follow-up
The age, sex distribution, smoking, and drinking did not
significantly differ between the two groups (Table 1). At
baseline, no significant differences were observed in all clin-
ical and biochemical parameters between the control and
weight-loss groups; after the 12-week intervention, the
BMI, serum insulin levels, HOMA-IR score, and serum TG
levels were significantly decreased in the weight-loss group
compared with the control group (Table 1). In the control
group, the subjects showed slight but significant weight
gain (weight and BMI; all P < 0.001) during the interven-
tion, whereas the subjects in the weight-loss group showed
significant reductions in not only the weight and BMI (both
P < 0.001) but also the waist circumference (P < 0.001), sys-
tolic BP (P = 0.049), insulin levels (P = 0.001), and HOMA-
IR score (P = 0.003) following the intervention (Table 1). In
addition, these reductions in weight, BMI, and waist cir-
cumference in the weight-loss group were greater than
those in the control group after adjusting for the baseline
values (all P < 0.001) (Table 1). The serum insulin levels,
HOMA-IR score, and serum TG levels also showed signifi-
cantly greater decreases in the weight-loss group than in
the control group after adjusting for the baseline values (P
= 0.020, P = 0.034, and P = 0.022, respectively) (Table 1).
The estimated TEE (2144.6 ± 45.3 kcal/d vs. 2201.3 ±
59.3 kcal/d; P = 0.519), total calorie intake (TCI) (2105.8 ±
40.0 kcal/d vs. 2200.5 ± 50.3 kcal/d; P = 0.159), and percent-
age of macronutrient intakes (%CHO:%PRO:%FAT =
61:15:22 in both groups) did not significantly differ between
the two groups at baseline (data not shown). The subjects’
overall compliance with the weight-loss plan was good. The
estimated TCI of the weight-loss group at 12-week follow-
up was, on average, 1949.4 kcal (%CHO:%PRO:%FAT =
59:19:22); and the types of dietary fats [saturated fatty acids
(SFAs), monounsaturated fatty acids (MUFAs), and polyun-
saturated fatty acids (PUFAs)] ingested by the study partici-
pants did not demonstrate any changes during the
intervention (data not shown).
Effects of a 12-week mild calorie restriction on percent of
body weight change, abdominal fat areas (CT), and body
composition (DEXA)
Table 2 presents the effects of a 12-week mild calorie-
restricted diet on the percent of body weight change,
abdominal fat area measured by CT, and body compos-
ition measured by DEXA. Comparison of the percent of
body weight changes (differences from baseline) revealed
that the weight-loss group had greater reductions in the
percent of body weight change than the control group
(0.63 ± 0.15 vs. -3.44 ± 0.34; P < 0.001). Regarding the re-
sults of CT, no significant differences were observed in
the L4 abdominal fat area (whole fat area and VFA), L4
subcutaneous fat area, or visceral-to-subcutaneous area
ratio (VSR) at baseline between the control and weight-
loss groups. At follow-up, the L4 VFA in the weight-loss
group was lower than in the control group (P < 0.001).
The VFA decreased by 17.7 cm2 (15%) from baseline in
the weight-loss group (P < 0.001), and the VSR decreased
by 0.09 from baseline in the weight-loss group (P <
0.001). Significantly greater reductions in the L4 VFA
and VSR were observed in the weight-loss group com-
pared with the control group (all P < 0.001). No statisti-
cally significant shifts in the VFA, subcutaneous fat area,
or VSR were identified in the control group (Table 2).
With regard to the DEXA results, there were no signifi-
cant differences in the fat percentage, fat mass, or lean
body mass between the two groups at both baseline and
follow-up (Table 2). After the intervention, significant
decreases in the fat percentage and fat mass were ob-
served in both the control and weight-loss groups; how-
ever, greater reductions in the fat percentage and fat
mass were observed in the weight-loss group than in the
control group after adjustment for the baseline values
(P = 0.006 and P < 0.001, respectively). The control group
showed a significant increase in the lean body mass,
whereas the weight-loss group showed a significant de-
crease in the lean body mass at the 12-week follow-up;
these changes were significantly different between the
two groups (P < 0.001) (Table 2).
Effects of mild calorie restriction on circulating fatty acid
profiles and desaturase activities at baseline and follow-up
Table 3 presents the effects of a 12-week mild calorie-
restricted diet on plasma fatty acid profiles. At baseline,
no significant difference was observed in the SFAs,
MUFAs, n-6 PUFAs, and n-3 PUFAs between the con-
trol and weight-loss groups. The total SFAs, including
palmitic acid (C16:0) and stearic acid (C18:0), decreased
from baseline in the weight-loss group; in addition, these
reductions were significantly greater than those in the
control group after adjusting for the baseline values (P =
0.027, P = 0.033, and P = 0.021, respectively). At follow-
up, the weight-loss group showed significantly lower
levels of total SFAs (P = 0.029), lauric acid (C12:0) (P =
0.032), and palmitic acid (C16:0) (P = 0.028) than the
control group. Similarly, the total MUFAs, including pal-
mitoleic acid (C16:1, n-7) and oleic acid (C18:1, n-9), de-
creased from baseline in the weight-loss group, and
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these decreases were significantly greater than those in
the control group after adjustment for the baseline
values (P = 0.017, P = 0.006, and P = 0.018, respectively).
At follow-up, the weight-loss group showed significantly
lower levels of total MUFAs (P = 0.021), palmitoleic acid
(C16:1, n-7) (P = 0.018), and oleic acid (C18:1, n-9) (P =
0.024) than did control group. Although the total n-6
and n-3 PUFA levels did not significantly change, eicosa-
dienoic acid (C20:2, n-6) and dihomo-γ-linolenic acid
(C20:3, n-6) decreased from baseline in the weight-loss
group. Both showed greater reductions in the weight-
loss group than in the control group after adjusting for
the baseline values (P < 0.001 and P = 0.003, respect-
ively). At follow-up, the weight-loss group showed sig-
nificantly lower levels of eicosadienoic acid (C20:2, n-6)
(P < 0.001) and dihomo-γ-linolenic acid (C20:3, n-6) (P
= 0.001) than the control group (Table 3).
C16 Δ9-desaturase activity significantly decreased
from baseline in the weight-loss group, and this reduc-
tion was greater in the weight-loss group than in the
control group after adjusting for the baseline values (P =
0.014). The activity of Δ5-desaturase significantly in-
creased from baseline in the weight-loss group, and this
increase was greater in the weight-loss group than in the
control group after adjusting for the baseline values (P =
0.001). In addition, at follow-up, Δ5-desaturase activity
was significantly higher in the weight-loss group than in
the control group (P < 0.001). Elongase activity signifi-
cantly decreased after the intervention (Table 3).
Relations between changes in L4 VFA and changes in
clinical/biochemical characteristics and fatty acid levels
Overall, 22 variables showed significant changes in the
weight-loss group compared with the control group after
adjusting for the baseline values [Table 1: weight, BMI,
waist circumference, insulin, HOMA-IR, and TGs; Table
2: whole fat area, VFA, VSR, fat percentage, fat mass, and
lean body mass; Table 3: SFAs, palmitic acid (C16:0), ste-
aric acid (C18:0), MUFAs, palmitoleic acid (C16:1, n-7),
oleic acid (C18:1, n-9), eicosadienoic acid (C20:2, n-6),
dihomo-γ-linolenic acid (C20:3, n-6), C16 Δ9-desaturase,
and Δ5-desaturase]. A correlation analysis between
changes in L4 VFA and changes in these variables was
performed. Of the total study subjects (n = 75), the
changes in L4 VFA demonstrated significant positive cor-
relations with changes in weight (r = 0.596, P < 0.001),
BMI (r = 0.596, P < 0.001), waist circumference (r = 0.317,
P = 0.006), insulin (r = 0.259, P = 0.025), fat percentage (r
= 0.241, P = 0.037), fat mass (r = 0.381, P = 0.001), lean
body mass (r = 0.464, P < 0.001), and dihomo-γ-linolenic
acid (C20:3, n-6) (r = 0.235, P = 0.042) and a significant
negative correlation with changes in Δ5-desaturase activ-
ities (r = −0.277, P = 0.016) (Fig. 1).
Discussion
VFA is associated with plasma fatty acid profiles and
lifestyle patterns [17]. We investigated the effects of
weight loss by mild calorie restriction (a 300 kcal/day in-
take reduction) on circulating fatty acid profiles and
desaturase activities in nondiabetic and overweight sub-
jects with high VFA (L4 VFA ≥100 cm2). The 12-week
intervention led to a 3.4% body weight loss and a 15%
VFA loss in the participants in the weight-loss group. In
addition, the study showed enhancement of plasma fatty
acid profiles (SFAs and MUFAs), greater decreases in
C16 Δ9-desaturase activity, and greater increases in Δ5-
desaturase activity in the weight-loss group compared
with the control group.
An inverse relation between Δ5-desaturase activity and
diabetes risk [18] and direct relations among C16 Δ9-
desaturase activity, insulin resistance, and abdominal
obesity [5] have been reported. In the present study, a
VFA loss was significantly related to Δ5-desaturase activity
but not to C16 Δ9-desaturase activity. Although some evi-
dence supports the inverse relation between Δ5-
desaturase activity and diabetes risk [18–22], the Δ5-
desaturase activity of this study did not correlate to insulin
and HOMA-IR, which are risk factors of type 2 diabetes.
However, the weight-loss group showed greater reductions
in the serum insulin levels and HOMA-IR scores than the
control group; furthermore, changes in insulin and
HOMA-IR were positively correlated with changes in
weight and BMI, which showed a significant negative cor-
relation with changes in Δ5-desaturase activity. Because
weight and BMI are also closely related to the risk of type
2 diabetes [23, 24], our results might indicate an indirect
inverse association between Δ5-desaturase activity and the
risk of type 2 diabetes (Fig. 2). Consequently, mild calorie-
restriction-induced weight loss in individuals with high
VFA might lead to the potential benefit of a reduced risk of
type 2 diabetes by improving fatty acid desaturase activity.
Estimated Δ5-desaturase activity was expressed as the
ratio of arachidonic acid (20:4, n-6) to dihomo-γ-
linolenic acid (20:3, n-6). The increase in Δ5-desaturase
activity observed in the weight-loss group might result
from the greater decrease of dihomo-γ-linolenic acid
(20:3, n-6) than that observed in the control group be-
cause there were no significant changes in arachidonic
acid (20:4, n-6) in the control and weight-loss groups.
Indeed, changes in VFA were positively correlated with
changes in dihomo-γ-linolenic acid (20:3, n-6) (Fig. 1).
Therefore, the study indicated that the inverse relation
between VFA and Δ5-desaturase activity might be medi-
ated by an alteration of dihomo-γ-linolenic acid (20:3,
n-6), which is also significantly associated with VFA.
Although the total n-6 PUFAs did not significantly
change during the intervention, the subjects in the
weight-loss group showed decreases in not only dihomo-
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γ-linolenic acid (C20:3, n-6) but also eicosadienoic acid
(C20:2, n-6); and these reductions were greater than the
reductions detected in the control group (Table 3). Con-
sistent with our results, other studies have found that
obese individuals showed higher levels of dihomo-γ-
linolenic acid (C20:3, n-6) in plasma phospholipids, TGs,
and sterol esters than the controls [25, 26]. A recent
study emphasized the proadipogenic properties of n-6
PUFAs [27]; indeed, several studies have found that n-6
PUFAs promote adipogenesis and increase the expres-
sion of lipogenic genes [27, 28]. Muhlhausler BS et al.
[27] concluded that n-6 PUFAs promote the expansion
of fat depots by up-regulating both hyperplasia and
hypertrophy; in other words, an accumulation of n-6
PUFAs might exacerbate an obese status by enhanced
adipogenesis, which could lead to several obesity-related
Fig. 1 Correlation matrix among major clinical parameters, fatty acids, and fatty acid desaturases (changed values). Correlations were obtained by
identifying a Pearson’s correlation coefficient. Red indicates a positive correlation, and blue indicates a negative correlation
Fig. 2 Summary of an indirect association between Δ5-desaturase activity and the risk of type 2 diabetes in the present study. Although no signifi-
cant and direct correlation between Δ5-desaturase activity and the risk of type 2 diabetes was observed in this study, connections among Δ5-
desaturase activity, weight, BMI, serum insulin level, and HOMA-IR score indicate an indirect inverse correlation between Δ5-desaturase activity and the
risk of type 2 diabetes. Because the visceral fat area (VFA) has a significant negative correlation with Δ5-desaturase activity and Δ5-desaturase activity is
inversely related to the risk of type 2 diabetes, VFA and the risk of type 2 diabetes might be positively correlated. Thus, mild calorie-restriction-induced
weight loss that affects VFA at L4 decrease might lead to health benefits
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health risks, including IR, metabolic syndrome, and dia-
betes [1]. Therefore, lowering the n-6 PUFA levels by
calorie-restriction-induced weight loss is necessary, and
the reduction of VFA to lower n-6 PUFAs is important.
In this study, the weight-loss group showed significant
decreases in total SFAs, including palmitic acid (C16:0)
and stearic acid (C18:0), which have previously been ob-
served to be related to the incidence of type 2 diabetes
[29, 30]. Total MUFAs, including palmitoleic acid
(C16:1, n-7) and oleic acid (C18:1, n-9), were also signifi-
cantly decreased in the weight-loss group of this study.
The palmitoleic acid (C16:1, n-7) plasma concentrations
mostly showed de novo hepatic fatty acid synthesis from
palmitic acid (C16:0) by C16 Δ9-desaturase [31, 32]; in
the present study, both palmitic acid (C16:0) and C16
Δ9-desaturase activity were significantly decreased dur-
ing the 12-week intervention in the weight-loss group,
which indicates that these alterations might affect
plasma concentrations of palmitoleic acid (C16:1, n-7).
Mice supplemented with palmitoleic acid exhibit higher
fat deposition, hepatic steatosis, and increased hepatic
expression of sterol regulatory element-binding protein
1c and fatty acid synthase, demonstrating the pro-
lipogenic effect of this MUFA [33]. Moreover, studies
conducted on humans have observed a detrimental in-
fluence of this MUFA on health [34, 35]. A previous
study found that high levels of palmitoleic acid (C16:1,
n-7) are associated with an increased risk of cardiovas-
cular disease [34] and are positively associated with
metabolic syndrome [35], including hypertriglyceridemia
[34] and abdominal obesity [36]. In the present study,
the weight-loss group, which presented significantly de-
creased levels of palmitoleic acid (C16:1, n-7), showed
greater reductions in serum TGs and waist circumfer-
ence than the control group. Therefore, reduced levels
of SFAs and MUFAs via calorie-restriction-induced
weight and VFA loss might yield future health benefits.
One of the major points of the present study is the cor-
relation of weight loss with a significant reduction of VFA.
As discussed thus far, many changes observed in the
weight-loss group of this study might be explained by the
VFA change. However, there is controversy regarding
whether visceral fat is more harmful to circulating fatty
acids than subcutaneous fat. Jensen MD [37] reported that
visceral fat is not a source of excess systemic free fatty acid
availability; conversely, Björntorp P [38] concluded that vis-
ceral fat tissue could be a significant source of free fatty
acids that might exert complex metabolic effects. Indeed,
several studies have suggested that large visceral fat depots
flooded the liver and the systemic circulation in the form of
free fatty acids [39, 40]. In addition, Klein S [41] observed
that excess visceral fat is more harmful than excess sub-
cutaneous fat because the lipolysis of TGs in visceral adi-
pose tissue releases free fatty acids into the portal vein,
which directly delivers them to the liver. Nielsen et al. [42]
demonstrated that the contribution of free fatty acids
derived from visceral fat to the portal and systemic circula-
tion increases with increases in the visceral fat mass. Be-
cause evidence that supports our results exists, we believe
that visceral fat is an important factor affecting the circulat-
ing fatty acid profiles.
A limitation of this study is its small sample size. Add-
itionally, our results might not be generalizable because
the study subjects were limited to nondiabetic overweight
Korean subjects. Finally, we did not exclude subjects who
took a medication that affects lipid metabolism. Only two
subjects in the control group took a lipid-lowering medi-
cation; the clinical/biochemical parameters and fatty acid
profiles did not show any significant differences between
the control groups according to medication [n = 38
(original control group) vs. n = 36 (control group w/o
medication)] (data not shown). In addition, the baseline
value-adjusted statistical significance of the changed
values between the control group without medication and
the weight-loss group was identical to the present results
(data not shown). Therefore, in this study, medication was
not considered a confounding factor in interpreting the
research results. Despite these limitations, this study dem-
onstrates that a weight-loss intervention based on a hypo-
caloric diet in overweight subjects with high visceral fat
levels improved not only the anthropometric and bio-
chemical parameters but also the fatty acids plasma levels.
Conclusions
An analysis of plasma fatty acid profiles identified signifi-
cant decreases in palmitic acid (C16:0), stearic acid (C18:0),
palmitoleic acid (C16:1), oleic acid (C18:1), eicosadienoic
acid (C20:2, n-6), and dihomo-γ-linolenic acid (C20:3, n-6)
as well as a decrease in C16 Δ9-desaturase activity and an
increase in Δ5-desaturase activity. These results suggest
that maintenance of high VFA levels without treatment
does not produce changes in the plasma fatty acid profiles,
whereas even mild weight loss with reduced VFA improves
the overall plasma fatty acid profile and desaturase activ-
ities. Through enhancement of the plasma fatty acid pro-
files, individuals may receive potential health benefits of
reduced future risks of type 2 diabetes and cardiovascular
disease. Moreover, eating behavior modification (mild
calorie restriction) might be an effective therapy for the
treatment of diseases such as type 2 diabetes and cardiovas-
cular disease.
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